Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing
# Background Clinical complications of long-term anticoagulation in patients with atrial fibrillation cause significant morbidity and have a substantial economic impact on the healthcare system. # Objective To assess the cost-benefit by implementing patient self-testing (PST) in German patients ant...
Saved in:
| Main Authors: | Roland Diel, Niklas Lampenius |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2019-08-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/9774 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation
by: Anetta Undas, et al.
Published: (2019-12-01) -
Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
by: Kevin Bowrin, et al.
Published: (2020-01-01) -
Rapid Point-of-Care Influenza Testing for Patients in German Emergency Rooms – A Cost-Benefit Analysis
by: Roland Diel, et al.
Published: (2019-12-01) -
Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis
by: Ze Li, et al.
Published: (2022-01-01) -
Comorbidity in elderly patients with atrial fibrillation affects the “cost of illness”
by: S. V. Malchikova, et al.
Published: (2019-10-01)